挣中国人的钱给外国人分，科兴这是想干啥？

Group 1 - The core point of the article revolves around the controversial dividend distribution by Sinovac Biotech, which is set to distribute a total of up to $124 per share, raising concerns among the public regarding the source of its profits and the implications for national interests [2][4][5] - Sinovac plans to issue a cash dividend of $55 per share on July 7, followed by an additional $19 per share after a special shareholders' meeting on July 8, with future dividends projected to be between $20 to $50 per share [2] - The total dividend distribution is estimated to amount to 53.4 billion RMB, which is nearly 20 times its market value of $389 million at the time of suspension [2] Group 2 - Sinovac's ownership structure is complex, with the largest shareholder being foreign institution Sequoia Capital holding 15.07%, and foreign investors collectively owning about 25%, while the founder holds only 8.85% [4] - The company reportedly earned $14.5 billion in 2021, raising questions about the legitimacy of its profits, which were largely driven by government-mandated vaccinations [4][5] - Public sentiment is critical of the company's actions, with many perceiving the dividend distribution as a betrayal of national interests, especially given the unclear efficacy of the vaccines administered [4][5][8]